MCID: PYL005
MIFTS: 56

Pyelonephritis

Categories: Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pyelonephritis

MalaCards integrated aliases for Pyelonephritis:

Name: Pyelonephritis 11 75 28 53 43 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:11400
ICD9CM 34 590.80
MeSH 43 D011704
NCIt 49 C34965
SNOMED-CT 68 45816000
ICD10 31 N16
UMLS 71 C0034186

Summaries for Pyelonephritis

MalaCards based summary: Pyelonephritis is related to chronic pyelonephritis and acute pyelonephritis. An important gene associated with Pyelonephritis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitrofurantoin and Icodextrin have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and spleen, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Wikipedia: 75 Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most... more...

Related Diseases for Pyelonephritis

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1270)
# Related Disease Score Top Affiliating Genes
1 chronic pyelonephritis 32.5 UMOD CRP ALB ACE
2 acute pyelonephritis 31.9 TNF TLR4 NAGLU LCN2 IL6 IL1B
3 acute cystitis 31.6 UMOD TLR4 LCN2 IL6 CXCL8
4 cystitis 31.6 UMOD TNF TLR4 IL6 CXCL8 CRP
5 nephrolithiasis, calcium oxalate 31.5 UMOD NAGLU AMBP
6 pyuria 31.2 LCN2 IL6 GPT CRP ALB
7 renal tuberculosis 31.2 CRP ALB
8 hydronephrosis 31.0 NAGLU LCN2 IL6 CXCL8 CRP CCL2
9 fasciitis 30.9 TNF IL6 CXCL8
10 pyelitis 30.8 UMOD TNF TLR4 LCN2 IL6 IL1B
11 bacteriuria 30.8 UMOD TLR4 IL6 CXCR2 CXCR1 CXCL8
12 neurogenic bladder 30.8 CRP CALCA ALB ACE
13 urinary tract infection 30.8 UMOD TNF TLR4 LCN2 IL6 IL1B
14 kidney papillary necrosis 30.8 UMOD ALB ACE
15 vesicoureteral reflux 30.8 UMOD NAGLU LCN2 CXCL8 CRP AMBP
16 urolithiasis 30.8 UMOD IL6 IL1B CCL2 AMBP ALB
17 amyloidosis 30.7 TNF IL6 IL1B CRP ALB
18 serum amyloid a amyloidosis 30.7 TNF IL6 CRP ALB
19 diabetes mellitus, ketosis-prone 30.7 GPT CRP ALB ACE
20 nephrosclerosis 30.7 TNF CCL2 ACE
21 toxic shock syndrome 30.7 TNF TLR4 IL6 IL1B IL10 CXCL8
22 optic papillitis 30.7 TNF CRP ACE
23 anuria 30.6 LCN2 CRP ALB ACE
24 cholecystitis 30.6 TLR4 GPT CRP CALCA ALB
25 renal hypertension 30.6 CRP ALB ACE
26 neutrophilia, hereditary 30.6 IL6 CSF3 CRP
27 splenic abscess 30.6 GPT CRP ALB
28 interstitial nephritis 30.5 UMOD TNF LCN2 CRP ALB ACE
29 acute kidney failure 30.5 UMOD LCN2 IL6 GPT AMBP ALB
30 infective endocarditis 30.5 IL6 CXCL8 CRP ALB ACE
31 carbuncle 30.5 TNF IL6 IL1B ALB
32 emphysematous cholecystitis 30.5 GPT CRP
33 microvascular complications of diabetes 3 30.5 NAGLU ALB ACE
34 necrotizing fasciitis 30.5 TNF IL6 IL1B CXCL8 CRP ALB
35 glomerulonephritis 30.4 TNF LCN2 IL6 IL1B IL10 CRP
36 adult respiratory distress syndrome 30.4 TNF IL6 IL1B IL10 CXCL8 CRP
37 pleural empyema 30.4 IL6 GPT CRP ALB
38 microvascular complications of diabetes 1 30.4 CXCL8 CXCL10 CCL2
39 urinary tract obstruction 30.4 UMOD TNF NAGLU LCN2 IL6 IL1B
40 uremia 30.4 TNF IL6 IL1B CRP ALB ACE
41 klebsiella pneumonia 30.4 GPT CRP ALB
42 prostatitis 30.4 TNF IL6 IL1B IL10 CXCL8 CXCL10
43 endophthalmitis 30.4 TNF IL6 IL1B CXCL8 CRP ALB
44 endocarditis 30.3 TNF LCN2 IL6 IL10 CXCL8 CRP
45 haemophilus influenzae 30.3 TNF IL1B CXCL8
46 discitis 30.3 CRP CALCA ALB
47 nutritional deficiency disease 30.2 IL6 CRP ALB
48 diverticulitis 30.2 TNF IL6 CXCL10 CRP ALB
49 hypertensive heart disease 30.2 IL6 CRP ACE
50 prostatic hypertrophy 30.2 CRP ALB ACE

Comorbidity relations with Pyelonephritis via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease, Familial, 1
Chronic Kidney Disease Cystitis
Decubitus Ulcer Deficiency Anemia
Esophagitis Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Iron Deficiency Anemia
Kidney Disease Nephrolithiasis, X-Linked Recessive, with Renal Failure
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Schizophreniform Disorder
Ureterolithiasis

Graphical network of the top 20 diseases related to Pyelonephritis:



Diseases related to Pyelonephritis

Symptoms & Phenotypes for Pyelonephritis

GenomeRNAi Phenotypes related to Pyelonephritis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.17 ACE ALB AMBP CALCA CCL2 CRP
2 no effect GR00402-S-2 10.17 ACE ALB AMBP CALCA CCL2 CRP
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.8 CXCL8 IL10 IL1B LCN2 TNF UMOD
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.8 ACE CXCL8 IL10 IL1B LCN2 TNF
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.8 UMOD

MGI Mouse Phenotypes related to Pyelonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 ACE ALB CALCA CCL2 CRP CXCL10
2 neoplasm MP:0002006 10.16 ACE ALB CALCA CCL2 CXCR2 IL10
3 renal/urinary system MP:0005367 10.13 ACE ALB CALCA CSF3 CXCR2 IL6
4 cellular MP:0005384 10.13 ACE ALB AMBP CCL2 CXCL10 CXCR2
5 cardiovascular system MP:0005385 10.13 ACE ALB CALCA CCL2 CRP CXCL10
6 liver/biliary system MP:0005370 10.1 ACE ALB CCL2 CXCR2 IL10 IL6
7 immune system MP:0005387 10.03 ACE ALB CCL2 CRP CSF3 CXCL10
8 skeleton MP:0005390 9.73 CALCA CCL2 CXCR1 CXCR2 GPT IL10
9 hematopoietic system MP:0005397 9.44 ACE CCL2 CSF3 CXCL10 CXCR1 CXCR2

Drugs & Therapeutics for Pyelonephritis

Drugs for Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
2
Icodextrin Approved, Investigational Phase 4 337376-15-5
3
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
4
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
5
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
6
Avibactam Approved Phase 4 1192500-31-4
7
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
8
Tigecycline Approved Phase 4 220620-09-7 5282044
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5, 39831-55-5 37768
11
Ceftriaxone Approved Phase 4 73384-59-5 5479530
12
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065
13
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
14
Ofloxacin Approved Phase 4 82419-36-1 4583
15
Amdinocillin Investigational, Withdrawn Phase 4 32887-01-7 36273
16 Fluoroquinolones Phase 4
17 Antitubercular Agents Phase 4
18 Avibactam, ceftazidime drug combination Phase 4
19 Technetium Tc 99m Dimercaptosuccinic Acid Phase 4
20 Anti-Bacterial Agents Phase 4
21 Anti-Infective Agents Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23
Ceftolozane Approved, Investigational Phase 3 689293-68-3 75984602
24
Ertapenem Approved, Investigational Phase 3 153832-46-3 150610
25
Piperacillin Approved Phase 3 66258-76-2 43672
26
Vaborbactam Approved, Investigational Phase 3 1360457-46-0
27
Sulbactam Approved Phase 3 68373-14-8 5316
28
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
29
Pentetic acid Approved Phase 3 67-43-6
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
32
Tazobactam Approved Phase 3 89786-04-9 123630
33
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
34
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
35
Ceftibuten Approved, Investigational Phase 3 97519-39-6 5282242
36
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
37
Doripenem Approved, Investigational Phase 3 148016-81-3 73303
38
Clavulanic acid Approved, Vet_approved Phase 3 58001-44-8 5280980
39
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 3 461-06-3
40 Omega 3 Fatty Acid Phase 3
41 Enmetazobactam Phase 3
42 Piperacillin, Tazobactam Drug Combination Phase 3
43 Antineoplastic Agents, Hormonal Phase 3
44 Hormones Phase 3
45 Hormone Antagonists Phase 3
46 Antiemetics Phase 3
47 glucocorticoids Phase 3
48 Anti-Inflammatory Agents Phase 3
49 Gastrointestinal Agents Phase 3
50 beta-Lactamase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Unknown status NCT03179384 Phase 4 Ceftriaxone
2 Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
3 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence. Completed NCT00136656 Phase 4 antibiotic;antibiotics
4 Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
5 Efficacy and Safety Study of Short Term Antibiotic During Seven Days With Ceftriaxone Intravenous the First Day Then Cefixime the Second Day Till the Seventh Day of Acute Uncomplicated Pyelonephritis in Women Between 18 and 65 Years Old Completed NCT01390623 Phase 4 Ceftriaxone
6 The Efficacy and Safety of Pivmecillinam in Treating Bacteriemic Urosepsis Caused by E.Coli Completed NCT03282006 Phase 4 pivmecillinam
7 Management of Sub-Clinical Bacteriuria in Pregnancy: A Feasibility Trial Completed NCT03275623 Phase 4 Antibiotic
8 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
9 Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion Completed NCT02598362 Phase 4 ciprofloxacin
10 AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS IN CHINESE ADULTS Recruiting NCT04882085 Phase 4 Zavicefta, Ceftazidime-Avibactam;Best Available Treatment
11 3-day Intravenous Antibiotic Treatment Versus 3-day Intravenous Followed by 7-day Oral Antibiotic Treatment for Acute Pyelonephritis in Children 1 Month to 3 Years Old: a Non-inferiority Open Randomized Multicentric Clinical Trial Not yet recruiting NCT05544565 Phase 4 IV Antibacterial Agents;Orally antibacterial agents
12 TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study Terminated NCT00239161 Phase 4 Levofloxacin
13 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
14 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
15 A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection Completed NCT02728089 Phase 3 MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
16 A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed NCT03788967 Phase 3 TBPM-PI-HBr;Ertapenem;Dummy Infusion;Dummy tablets
17 A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. Completed NCT03687255 Phase 3 cefepime/AAI101 combination;Piperacillin/tazobactam
18 A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis Completed NCT03840148 Phase 3 Cefepime/VNRX-5133 (taniborbactam);Meropenem
19 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
20 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
21 A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
22 A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00229021 Phase 3 doripenum
23 A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00210990 Phase 3 doripenem
24 A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
25 A Phase 2, Randomized, Double-blind, Positive-control, Multicenter, Prospective Study to Assess Efficacy and Safety of Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed NCT04505683 Phase 2, Phase 3 Benapenem;Ertapenem
26 Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
27 A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT01345929 Phase 3 CXA-201;Levofloxacin
28 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
29 Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
30 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
31 Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
32 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
33 Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children:A Multi-centre, Double-blind, Randomized, Placebo-controlled, Clinical Trial Recruiting NCT04654507 Phase 3 Dexamethasone Oral;Placebo
34 A Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults Recruiting NCT04979806 Phase 3 Cefepime-zidebactam (FEP-ZID);Meropenem
35 Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial. Not yet recruiting NCT05597540 Phase 3 Short antibiotic treatment;Usual antibiotic treatment
36 A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis.(EudraCT no. 2022-000061-40) Not yet recruiting NCT05204368 Phase 3 Combination of Imipenem/Cilastatin and XNW4107;Meropenem
37 A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults Not yet recruiting NCT03630081 Phase 3 FEP-TAZ 4 g;Meropenem;ciprofloxacin 500 mg Optional Oral Switch
38 Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood. Terminated NCT00724256 Phase 3 ceftibuten
39 A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis Terminated NCT02302092 Phase 3 Flomoxef;Cefepime
40 A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections Terminated NCT01110408 Phase 3 Doripenem;Doripenem placebo;Cefepime;Cefepime placebo;Amoxicillin/clavulanate potassium
41 A Randomized Controlled Trial of Antibiotic Prophylaxis in Children With Pyelonephritis in the Abscence of Vesicoureteral Reflux Withdrawn NCT00752375 Phase 3 Trimethoprim Sulfamethoxazole;placebo
42 A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli Unknown status NCT02537847 Phase 2 Sitafloxacin;Ertapenem
43 A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin Completed NCT02321800 Phase 2 Cefiderocol;Imipenem/cilastatin
44 Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT03680612 Phase 2 Cefepime 1G - 2G / AAI101 0.5G - 0.75G;cefepime 1 g or cefepime 2 g
45 A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation. Completed NCT01928433 Phase 2 Finafloxacin 800 mg i.v. once daily;Finafloxacin placebo i.v. once daily;Finafloxacin 800 mg tablets once daily;Finafloxacin placebo tablets once daily;Ciprofloxacin 400 mg i.v. twice daily;Ciprofloxacin placebo i.v. twice daily;Ciprofloxacin 500 mg oral twice daily;Ciprofloxacin placebo oral twice daily
46 A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of iv or iv/po Omadacycline and iv/po Levofloxacin in the Treatment of Adults With Acute Pyelonephritis. Completed NCT03757234 Phase 2 Omadacycline;Levofloxacin
47 Study of the Effect of Acetylcysteine on Inflammation Biomarkers in Pediatric Acute Pyelonephritis. Completed NCT02080182 Phase 2 Acetylcysteine;placebo acetylcysteine
48 A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT03230838 Phase 2 Ceftolozane/Tazobactam;Meropenem
49 A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis Completed NCT01096849 Phase 2 levofloxacin;plazomicin;placebo
50 A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT00921024 Phase 2 CXA-101;Ceftazidime

Search NIH Clinical Center for Pyelonephritis

Cochrane evidence based reviews: pyelonephritis

Genetic Tests for Pyelonephritis

Genetic tests related to Pyelonephritis:

# Genetic test Affiliating Genes
1 Pyelonephritis 28

Anatomical Context for Pyelonephritis

Organs/tissues related to Pyelonephritis:

MalaCards : Kidney, Liver, Spleen, Spinal Cord, Neutrophil, Prostate, Small Intestine

Publications for Pyelonephritis

Articles related to Pyelonephritis:

(show top 50) (show all 13503)
# Title Authors PMID Year
1
Urinary N-acetyl-beta-D-glucosaminidase as a diagnostic marker of acute pyelonephritis in children. 53 62
19367005 2008
2
Doripenem: a review of its use in the treatment of bacterial infections. 53 62
18778123 2008
3
The multiple functions of Tamm-Horsfall protein in human health and disease: a mystery clears up. 53 62
15989109 2005
4
Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. 53 62
15816991 2005
5
In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. 53 62
11801667 2002
6
Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. 53 62
11260138 2001
7
[Microproteinuria and enzymuria in fever and pyelonephritis in childhood. A prospective study of 180 children]. 53 62
9123685 1997
8
[Evaluation of N-acetyl-beta glucosaminidase in upper and lower urinary tract infections in childhood. Clinical study of 168 children]. 53 62
9064498 1996
9
dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor. 53 62
7537246 1995
10
Urinary N-acetyl-beta-glucosaminidase and beta-2-microglobulin in the diagnosis of urinary tract infection in febrile infants. 53 62
8036046 1994
11
Urinary N-acetyl-beta-glucosaminidase in normal Chinese children and children with pyelonephritis. 53 62
2063674 1991
12
Urinary N-acetyl-beta-glucosaminidase and the selection of children for radiologic evaluation after urinary tract infection. 53 62
2371096 1990
13
Atypical presentation of focal xanthogranulomatous pyelonephritis. 62
36439935 2023
14
I saw the "bear paw" sign - Massive renal xanthogranulomatous pyelonephritis. 62
36410078 2023
15
Post mortem computed tomography is highly sensitive for pyelonephritis. A radiologic-pathologic correlation series. 62
36210403 2022
16
A girl with hearing loss, dizziness, hypertension, and pyelonephritis with ureteral edema: Answers. 62
35507143 2022
17
A girl with hearing loss, dizziness, hypertension, and pyelonephritis with ureteral edema: Questions. 62
35507147 2022
18
Early versus Late acute graft pyelonephritis: A retrospective analysis of graft and patient outcomes. 62
35787934 2022
19
Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. 62
35788049 2022
20
Determining the effectiveness of the immature granulocyte percentage and systemic immune-inflammation index in predicting acute pyelonephritis. 62
36472407 2022
21
Neglected listeria infection in pregnancy in China: 93 cases. 62
35264053 2022
22
Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: An observational study. 62
35484899 2022
23
Costus spiralis extract restores kidney function in cisplatin-induced nephrotoxicity model: Ethnopharmacological use, chemical and toxicological investigation. 62
35772602 2022
24
Xanthogranulomatous Pyelonephritis - A Diagnostic and Therapeutic Dilemma. 62
36473546 2022
25
Preemptive liver transplant in two patients with primary hyperoxaluria type 1: Clinical significance of nephrolithiasis and nephrocalcinosis. 62
35979862 2022
26
Clinical presentation and management of urolithiasis in the obstetric patient: a matched cohort study. 62
33969780 2022
27
Hospitalizations for infections in primary Sjögren's syndrome patients: a nationwide incidence study. 62
36173925 2022
28
Evaluation of hymenal adhesions resection in the treatment of recurrent post-coital cystitis. 62
36224051 2022
29
Delays in Ureteroscopy and Shock Wave Lithotripsy After Ureteral Stent Placement: Impact on Infectious Complications, Resource Use, and Medical Costs. 62
36458475 2022
30
The prevalence of Mycoplasma hominis in Outpatients at a Tertiary Care Hospital in East India. 62
36382313 2022
31
First description of a clinical glutamine-dependent Escherichia coli with a missense mutation in the glnA. 62
35948249 2022
32
[Calico-venous fistulae: an intrarenal complication of percutaneous nephrolithotomy]. 62
36382824 2022
33
Role of Retrograde Intrarenal Surgery in the Management of Diabetic Renal Papillary Necrosis. 62
35531893 2022
34
[The influence of pyelovenous reflux on the development of acute pyelonephritis in an experimental model]. 62
36382813 2022
35
ACR Appropriateness Criteria® Acute Pyelonephritis: 2022 Update. 62
36436954 2022
36
[Blebbing of plasma membrane of lymphocytes in infectious complications of urolithiasis]. 62
36382815 2022
37
Unusual case of urothelial carcinoma disguised as xanthogranulomatous pyelonephritis and causing reno-colic fistula: Case report and review of literature. 62
36105829 2022
38
National Adherence to Guidelines for Antimicrobial Prophylaxis for Patients Undergoing Radical Cystectomy. 62
36383758 2022
39
Functional constipation as a risk factor for pyelonephritis and recurrent urinary tract infection in children. 62
36435986 2022
40
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints. 62
36374023 2022
41
Genomic analysis of a multidrug methicillin-resistant staphylococcus epidermidis recovered from the urine of a guinea pig (Cavia porcellus) with suspected pyelonephritis. 62
36323834 2022
42
[Two Cases of Emphysematous Pyelonephritis Successfully Treated by Transurethral Catheterization]. 62
36458398 2022
43
Assessment of nationally recommended antibiotics for treatment of UTI in U.S.-Mexico border emergency departments. 62
36027632 2022
44
Protective role for C3aR in experimental chronic pyelonephritis. 62
36250902 2022
45
An update on pyelonephritis: role of contrast enhancement ultrasound (CEUS). 62
36385692 2022
46
Renal mucormycosis following transurethral resection of prostate in the time of COVID-19: Unique imaging features resembling emphysematous pyelonephritis. 62
36438453 2022
47
Xanthogranulomatous Pyelonephritis: An Infrequent Entity in the Emergency Service. 62
35985523 2022
48
Contralateral necrotizing fascitis after left nephrectomy for emphysematous pyelonephritis. 62
36341196 2022
49
Tubercular empyema a sequalae of emphysematous pyelonephritis with porous diaphragm syndrome and its successful management: A case report. 62
36252542 2022
50
[Risk factors and mechanisms of acute pyelonephritis development after contact ureterolithotripsy]. 62
36382814 2022

Variations for Pyelonephritis

Expression for Pyelonephritis

Search GEO for disease gene expression data for Pyelonephritis.

Pathways for Pyelonephritis

Pathways related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TNF TLR4 LCN2 IL6 IL1B IL10
2
Show member pathways
13.87 TNF IL6 IL1B IL10 CXCR2 CXCR1
3
Show member pathways
13.68 CCL2 CSF3 CXCL10 CXCL8 CXCR1 CXCR2
4
Show member pathways
13.43 TNF TLR4 IL6 IL1B IL10 CXCR2
5
Show member pathways
13.38 CCL2 CSF3 CXCL10 CXCL8 IL10 IL1B
6
Show member pathways
13.35 TNF IL6 IL1B IL10 CXCR2 CXCR1
7
Show member pathways
12.91 TNF TLR4 IL6 IL1B CXCL8 CXCL10
8
Show member pathways
12.87 CXCR2 CXCR1 CXCL8 CXCL10 CCL2
9 12.77 IL6 IL1B IL10 CXCL10 CSF3 CCL2
10
Show member pathways
12.64 TNF IL6 IL1B IL10 CCL2
11 12.62 TNF IL1B IL10 CXCL10 CCL2
12
Show member pathways
12.59 TNF TLR4 IL6 IL1B CXCL8
13
Show member pathways
12.5 TNF TLR4 IL6 IL1B CXCL8 CXCL10
14
Show member pathways
12.39 TNF TLR4 IL6 IL1B CXCL8
15
Show member pathways
12.37 TNF IL6 CXCL8 CXCL10 CSF3 CCL2
16 12.26 CXCL8 IL10 IL1B IL6 TNF
17 12.16 TNF IL6 IL1B IL10
18
Show member pathways
12.14 CXCR2 CXCR1 CXCL8 CXCL10 CCL2
19 12.06 TNF IL6 IL10 CSF3
20
Show member pathways
12.02 TNF TLR4 IL6 IL1B IL10
21 11.97 CCL2 CXCL8 IL10 IL6
22 11.97 CCL2 CXCL10 CXCL8 IL1B IL6 TLR4
23
Show member pathways
11.96 TLR4 IL6 CXCL8 CSF3
24 11.95 TNF IL1B IL10 CXCL8
25 11.9 TNF LCN2 IL6 IL1B IL10 CXCL8
26
Show member pathways
11.87 IL6 CXCL8 CRP CCL2
27 11.85 IL10 IL1B IL6 TNF
28 11.83 TNF TLR4 IL6 IL10 CRP
29 11.81 TNF IL1B IL10
30 11.81 IL6 IL10 CXCL8 CCL2
31 11.78 TLR4 IL6 IL10
32
Show member pathways
11.77 TNF IL6 IL1B CXCL8
33 11.75 IL10 IL1B IL6 TLR4 TNF
34
Show member pathways
11.73 TNF TLR4 IL6 IL10
35 11.67 TNF TLR4 LCN2 IL6 IL10 CXCL8
36 11.64 IL6 CXCR1 CXCL8
37 11.64 CCL2 CXCL8 IL6 TLR4 TNF
38 11.63 TNF TLR4 IL1B CCL2
39 11.63 CCL2 CXCL8 CXCR2 IL10 TNF
40 11.62 TNF IL10 CCL2
41 11.6 TNF IL6 IL1B CALCA
42
Show member pathways
11.58 CXCL8 CXCR1 CXCR2
43 11.58 CCL2 CXCL10 TLR4
44 11.56 TNF IL6 CCL2
45 11.54 TNF TLR4 IL6 CXCL10 CCL2
46 11.5 TNF IL6 IL1B CXCL8 CSF3 CCL2
47 11.43 CCL2 CXCL8 IL6
48 11.43 TNF TLR4 IL6 IL1B CXCR2 CXCL8
49 11.42 TNF TLR4 IL6 IL1B IL10
50 11.39 TNF IL6 IL1B

GO Terms for Pyelonephritis

Cellular components related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.12 ACE ALB AMBP CALCA CCL2 CRP
2 external side of plasma membrane GO:0009897 9.93 TNF TLR4 CXCR2 CXCR1 CXCL10 ACE
3 extracellular space GO:0005615 9.81 ACE ALB AMBP CALCA CCL2 CRP

Biological processes related to Pyelonephritis according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.43 CALCA CCL2 CSF3 CXCL10 CXCL8 CXCR1
2 negative regulation of cell population proliferation GO:0008285 10.4 CXCL8 IL10 IL1B IL6 TNF UMOD
3 defense response to Gram-positive bacterium GO:0050830 10.27 CRP IL1B IL6 TNF
4 positive regulation of inflammatory response GO:0050729 10.25 TNF TLR4 IL1B ACE
5 positive regulation of interleukin-6 production GO:0032755 10.24 TNF TLR4 IL6 IL1B
6 positive regulation of DNA-binding transcription factor activity GO:0051091 10.24 CSF3 IL10 IL1B IL6 TNF
7 chemotaxis GO:0006935 10.23 CXCR2 CXCR1 CXCL8 CXCL10 CCL2
8 calcium-mediated signaling GO:0019722 10.22 TNF CXCR2 CXCR1 CXCL8
9 positive regulation of nitric oxide biosynthetic process GO:0045429 10.15 TNF TLR4 IL1B
10 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.14 TNF IL6 IL10
11 liver regeneration GO:0097421 10.11 TNF IL6 IL10
12 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.1 TNF TLR4 IL6
13 chemokine-mediated signaling pathway GO:0070098 10.1 CCL2 CXCL10 CXCL8 CXCR1 CXCR2
14 neutrophil chemotaxis GO:0030593 10.1 CCL2 CXCL10 CXCL8 CXCR1 CXCR2 IL1B
15 negative regulation of neurogenesis GO:0050768 10.09 TNF IL6 IL1B
16 receptor internalization GO:0031623 10.09 CXCR2 CXCR1 CXCL8 CALCA
17 response to bacterium GO:0009617 10.07 TNF TLR4 CXCL10 CCL2
18 positive regulation of glial cell proliferation GO:0060252 10.07 IL1B IL6 TNF
19 positive regulation of chemokine production GO:0032722 10.07 TNF TLR4 IL6 IL1B
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.06 TNF IL1B IL10
21 lipopolysaccharide-mediated signaling pathway GO:0031663 10.06 TNF TLR4 IL1B CCL2
22 immune response GO:0006955 10.06 CCL2 CSF3 CXCL10 CXCL8 CXCR1 CXCR2
23 positive regulation of interleukin-8 production GO:0032757 10.02 TNF TLR4 IL6 IL1B CALCA
24 response to lipopolysaccharide GO:0032496 10 UMOD TNF TLR4 IL1B IL10 CXCL10
25 inflammatory response GO:0006954 10 CALCA CCL2 CRP CXCL10 CXCL8 CXCR2
26 positive regulation of neuroinflammatory response GO:0150078 9.99 TNF IL6 IL1B
27 negative regulation of cytokine production involved in immune response GO:0002719 9.98 TNF IL10
28 positive regulation of fever generation GO:0031622 9.97 TNF IL1B
29 negative regulation of lipid storage GO:0010888 9.97 TNF IL6 CRP
30 cellular response to interleukin-17 GO:0097398 9.96 IL1B CXCL10
31 sequestering of triglyceride GO:0030730 9.95 TNF IL1B
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.93 IL1B TNF
33 negative regulation of gap junction assembly GO:1903597 9.91 IL1B ACE
34 interleukin-8-mediated signaling pathway GO:0038112 9.91 CXCR2 CXCR1
35 vascular endothelial growth factor production GO:0010573 9.91 TNF IL6 IL1B
36 chronic inflammatory response to antigenic stimulus GO:0002439 9.9 TNF IL10
37 positive regulation of leukocyte chemotaxis GO:0002690 9.87 IL6 CXCR2 CXCL10
38 response to external stimulus GO:0009605 9.73 TLR4 CXCL8 CXCL10
39 cellular response to lipopolysaccharide GO:0071222 9.55 TNF TLR4 IL6 IL1B IL10 CXCL8

Molecular functions related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 TNF TLR4 IL6 CXCL10 CSF3 CCL2
2 interleukin-8 binding GO:0019959 9.62 CXCR2 CXCR1
3 enterobactin binding GO:1903981 9.56 LCN2 ALB
4 interleukin-8 receptor activity GO:0004918 9.46 CXCR2 CXCR1
5 cytokine activity GO:0005125 9.44 TNF IL6 IL1B IL10 CXCL8 CXCL10

Sources for Pyelonephritis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....